VIP

VIP – Benefits & Side Effects

VIP – Protocol

VIP – Lifestyle Considerations

Proper Peptide Storage

Why Proper Peptide Storage Matters

Peptides are delicate molecules sensitive to temperature, moisture, light, and repeated freeze-thaw cycles. Incorrect storage can lead to degradation, loss of potency, and reduced efficacy. Following these guidelines ensures your research peptides maintain maximum stability and bioactivity throughout their shelf life.

Lyophilized (Powder) Peptides

Optimal Storage:

• Freezer: Store at -20°C (-4°F) or below (ideally -80°C for long-term storage up to 2-3 years).
• Short-term: Refrigerate at 2-8°C (35.6-46.4°F) for weeks to months.
• Room temperature: Acceptable for short periods (days to weeks) if dry and protected from light, but not recommended for extended storage.
• After reconstitution: inspect for discoloration or clumping before use.

Key Practices:

• Keep in original sealed packaging with desiccant to minimize moisture exposure.
• Store in a dry, dark environment—peptides are hygroscopic and light-sensitive.
• Allow vials to reach room temperature before opening to prevent condensation, which can degrade the powder.

Reconstituted (Liquid) Peptides

Refrigeration is Essential:

• Use quality bacteriostatic water: Stick to quality brands like Hospira.
• Store at 2-8°C (35.6-46.4°F) immediately after reconstitution.
• Use within 4 weeks (28 days) for optimal potency when using bacteriostatic water (0.9% benzyl alcohol).
• Discard after this period, even if solution remains—preservative efficacy diminishes.

Important Warnings:

• Do NOT freeze reconstituted solutions—freezing denatures peptides.
• Avoid freeze-thaw cycles—they cause irreversible degradation. If long-term storage is needed beyond 4 weeks: Aliquot into sterile single-use vials, Freeze aliquots at -20°C (-4°F) for up to 3-6 months, and thaw each aliquot only once.

Handling Peptides Best Practices

1. Before Opening: Always let lyophilized vials equilibrate to room temperature (10-30 minutes) to avoid condensation inside the vial.
2. Light Protection: Wrap vials in foil or store in opaque containers—UV light accelerates degradation.
3. Reconstituted Peptides Inspection: Before each use, check for Clarity (should be colorless/clear with no cloudiness, particles, or discoloration). Discard if any issues observed.
4. Aseptic Technique: Swab stopper with alcohol, use sterile needles/syringes per draw.
5. Labeling: Mark reconstitution date on vials.

Common Peptide Storage Mistakes to Avoid

• Moisture Exposure: Never store open vials; always reseal tightly.
• Temperature Fluctuations: Avoid door storage in fridge/freezer.
• Heat/Light: Keep away from direct sunlight, heaters, or lab lights.
• Overuse of Multi-Dose Vials: Follow 28-day rule per USP/CDC guidelines.
• Freezing Liquids: Repeated cycles can reduce potency by 25%+ per cycle.

Special Peptide Considerations

• Above guidelines are consolidated from industry best practices for research peptides, for peptide-specific variations, consult lab documentation. Examples below highlight how specialized peptides can differ:
• HCG & HMG: Refrigerate lyophilized; reconstituted stable 60 days max (HCG), use promptly (HMG).
• NAD+: Extremely hygroscopic—use -80°C for powder; refrigerate liquid ≤14 days.
• PT-141: Room temp stable short-term; refrigerate reconstituted ≤1 week.

Subcutaneous Peptide Injection Protocol

Subcutaneous Peptide Injection Protocol Overview

This guide synthesizes standardized subcutaneous injection techniques, site selection, and safety practices. Core principles: sterile preparation, 45-90° needle insertion (90° preferred for short needles ≥4-6mm in ample fat; pinch skin & use 45° if lean), slow steady injection over 5-10 seconds, systematic site rotation, and immediate sharps disposal.

Preparation & Supplies

• Hand Hygiene: Wash thoroughly with soap and water.
• Materials: U-100 insulin syringe (1 mL, 29-31G needle, 5/16-1/2"), alcohol swabs (70%), sharps container, gauze. Use 30-50 unit syringes for volumes <10 units.
• Vial Prep: Wipe stopper, dry 10-30 seconds, draw dose, tap out air bubbles. Warm vials to room temperature to reduce stinging.
• Volume Limit: ≤1.5 mL per site; split larger doses (e.g., 75 IU into 3x25 IU). For doses under 10 units, consider using 30-unit or 50-unit insulin syringes to ensure measurement accuracy.

Site Selection & Rotation

Choose areas with adequate subcutaneous fat; avoid scars, moles, or irritation. Systematically rotate sites 1-1.5 inches apart; avoid same spot for 1-2 weeks. Log sites to prevent lipohypertrophy/lumping:

• Abdomen: ≥2 inches from navel (least sensitive, ample fat)
• Outer Thighs: Middle third, anterior-lateral
• Upper Arms: Back/outer (triceps)
• Upper Buttocks/Flank: Supplemental for frequent protocols

Peptide Injection Technique

Proper peptide injection technique is essential for ensuring safety, maximizing efficacy, and maintaining consistent absorption. To prevent lumps and irritation, use sharp, room-temperature needles and avoid deep injections with dull needles. Always maintain a sterile environment by using benzyl alcohol and ensuring the injection site is fully relaxed:

1. Clean site outward in circles; air-dry 30 seconds.
2. Pinch 1-2 inch skin fold to lift subcutaneous layer.
3. Insert needle at 45-90° angle (90° for ample fat, 45° for lean/thin needle).
4. No aspiration (pulling back plunger to check for blood)
5. Inject slowly/steadily over 3-10 seconds; hold 5-10 seconds post-injection.
6. Withdraw at same angle; gentle pressure if bleeding.
7. Dispose in sharps container immediately; never recap.
8. Discard any reconstituted solution if it becomes cloudy. Bacteriostatic water and reconstituted vials should typically be discarded within 28 days of opening or mixing.

Peptide Injection Timing Consideration

• Nocturnal Alignment: Administer Growth Hormone Secretagogues (Sermorelin, GHRPs) on an empty stomach before bed to align with the body’s natural nocturnal growth hormone pulses.
• Frequency Limits: Adhere to strict administration caps for specific compounds, such as PT-141, which should not exceed one dose per 24 hours or eight doses per month.
• Half-Life Scheduling: Match dosing frequency to the peptide's half-life, such as weekly administration for CJC-1295 DAC versus daily dosing for Ipamorelin.
• Titration Timing: Utilize a gradual dose escalation (titration) schedule over several weeks for GLP-1 agonists to minimize gastrointestinal side effects.
• Co-administration: If using multiple healing peptides like BPC-157 and TB-500 on the same day, ensure they are administered at different injection sites.
• Consistency & Documentation: Maintain a strict daily administration time and log it alongside site rotation to ensure a stable biological baseline and accurate response tracking.

Peptide Post-Injection Care & Risks

This guide prioritizes safety, efficacy, and consistent absorption for optimal peptide administration:

• Monitor for redness/swelling; rest site 1-7 days if severe.
• No massage (disrupts absorption).
• Document dose, site, time, reactions.
• Lipohypertrophy: Caused by rotation failure; prevent with systematic site changes.
• Pain/Lumps: From deep injection, cold solution, or dull needles.
• Infection: Maintain asepsis; monitor for fever/redness.

VIP – Identification

Common Names and Designations:

• Vasoactive Intestinal Peptide (official designation)

• Vasoactive Intestinal Polypeptide (alternative designation)

• VIP (primary abbreviation)

• Peptide PHI (in relation to PHM-27/VIP-producing tissues)

• PHI/VIP (when discussing tissue co-expression)

• Avian VIP (species designation for chicken/bird VIP)

• Porcine VIP (species designation for pig VIP)

• Human VIP (species designation for human VIP)

CAS Number: 37221-79-7

Molecular Formula: C₁₄₇H₂₃₈N₄₄O₄₂S (human VIP)

Molecular Weight: 3325.83 Da (or 3326 g/mol)

FDA UNII: 6J2WVD66KR

PubChem CID: 53314964

Origin and Classification:

• Source: Natural; produced by enteric neurons, pancreatic islet cells, and neurons distributed throughout central and peripheral nervous systems

• Biosynthesis: Ribosomal origin; transcribed from VIP gene, translated as larger precursor peptide, then enzymatically processed to mature 28-amino acid peptide

• Functional Classification: Neurotransmitter; neuromodulator; neuropeptide; signaling peptide; immune modulator; vasodilator

• Structural Type: Linear peptide with no cyclic disulfide bonds

Amino Acid Sequence (Human):

• Sequence (N-terminus to C-terminus): His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn

• Sequence Length: 28 amino acids

• Single Letter Code: HSDAVFTDNYTRLRKQMAVKKYLNSILN

• HELM Notation: PEPTIDE1{H.S.D.A.V.F.T.D.N.Y.T.R.L.R.K.Q.M.A.V.K.K.Y.L.N.S.I.L.N}$$

Physicochemical Properties:

• Appearance: White to off-white lyophilized powder

• Solubility: Soluble in water and physiological buffers; commonly supplied as trifluoroacetate (TFA) salt for enhanced stability

• Biological Half-life: Approximately 2 minutes in blood plasma due to rapid proteolytic degradation by VIP-degrading endopeptidases

• Storage: Stable at -20°C or lower when protected from light and moisture; lyophilized form standard

• pH Stability: Stable in physiological pH range (7.0-7.4)

• Melting Point: >150°C (with decomposition)

• Charge Profile: Contains multiple charged amino acids (4 lysines, 4 arginines, acidic residues); net positive charge at physiological pH

• Isoelectric Point (pI): Approximately 8.5-9.0

Salt Forms and Formulations:

• Free peptide: H-HSDAVFTDNYTRLRKQMAVKKYLNSILN-OH

• Trifluoroacetate salt: VIP·TFA (most common form)

• Hydrochloride salt: VIP·HCl

• Acetate salt: VIP·CH₃COOH

• Lyophilized powder: Standard supply format

Precursor and Related Information:

• Precursor protein: VIP is derived from a larger precursor peptide (preprohormone) containing additional peptide sequences

• Related peptide: Peptide HM (PHM-27) is often co-released with VIP from the same precursor

• Species variants: Sequences show conservation across mammals with minor amino acid variations; chicken VIP differs at position 3 (Asn instead of Asp)

• VIP fragments: Biologically active fragments include VIP(1-12), VIP(10-28), and VIP(22-28) with distinct receptor selectivity

Receptor Interactions:

• VPAC1 receptor: Binds VIP with high affinity (Kd ~0.1-1 nM); coupled to Gs protein with adenylyl cyclase activation

• VPAC2 receptor: Binds VIP with high affinity (Kd ~0.1-1 nM); coupled to Gs protein with adenylyl cyclase activation; can also activate phospholipase C

• PAC1 receptor: Binds VIP with lower affinity compared to PACAP (Kd ~10-100 nM); shares partial agonism

• Receptor distribution: VPAC1 and VPAC2 widely distributed in intestinal epithelium, neurons, immune cells, endothelium, and brain

Pharmacological Classification:

• G protein-coupled receptor agonist

• Neuropeptide neurotransmitter

• Immune modulator

• Vasodilator

• Neuroendocrine regulator

• Anti-inflammatory agent

Regulatory and Clinical Status:

• Not approved as pharmaceutical in United States or European Union

• Investigated in clinical trials for inflammatory bowel disease, pancreatic cancer, and other conditions

• Used extensively as research reagent in neuroscience and immunology

• Stable synthetic analogs (agonists) in clinical development

Database Links and External References:

• PubChem: CID 53314964 - Complete chemical structure, synonyms, and properties

• UniProt: P04004 - Prepro-vasoactive intestinal peptide (Homo sapiens)

• NCBI Gene: Entrez Gene ID 7432 - VIP gene (Chromosome 6q24.2-q25)

• PDB: Structural information for VIP-receptor complexes

• IUPHAR/BPS Guide to Pharmacology: VPAC1 and VPAC2 receptor information

Note: VIP's extremely rapid enzymatic degradation (2-minute half-life) in blood plasma reflects its nature as a locally-acting neurotransmitter rather than a systemically-circulating hormone. This property has motivated development of VIP-resistant analogs (such as stearyl-norleucine VIP, BAY 55-9881) with extended half-lives suitable for therapeutic administration. The peptide's structure contains highly conserved regions across species, with functional studies often using porcine, chicken, or rat VIP interchangeably with human VIP due to sequence homology.

VIP – Research

VIP is a special tiny protein made in our bodies that acts like a messenger. It helps with things like relaxing blood vessels, calming down swelling in the body, and protecting brain cells. Scientists study it because it might help with serious health problems like lung issues, brain diseases, and too much inflammation. Here's research from trusted science sites like PubMed and PMC, explained simply.

Study: Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension
Benefits: Helps open up blood vessels in the lungs, slows down overgrowth of lung cells, and improves breathing for people with a rare lung disease called primary pulmonary hypertension (PPH). In tests, it stopped lung cells from growing too much and made patients feel better without big side effects.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC154449/
Summary: In this study from 2003, doctors tested VIP on patients with PPH, a deadly condition where lung blood pressure gets too high, leading to heart failure. They gave VIP by inhalation (breathing it in) at 200 micrograms a day. It worked by sticking to special spots on lung cells (called VPAC receptors), which were way more active in sick patients. This relaxed the blood vessels and stopped smooth muscle cells in the lungs from multiplying too fast—something that clogs up the lungs in PPH. In lab tests on cells from patients, VIP cut cell growth by up to 50% at certain doses. A small trial on five patients showed it was safe, lowered lung pressure during exercise, and improved life quality. No major side effects like drops in blood pressure happened. This suggests VIP could be a new breathing treatment, easier than other drugs that need IV tubes.

Study: Therapeutic potential of vasoactive intestinal peptide and its receptors
Benefits: Protects brain cells from dying in diseases like Parkinson's, reduces swelling and harmful brain chemicals by calming overactive immune cells in the brain.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC2967653/
Summary: This 2010 review looks at VIP's power in brain health. Parkinson's happens when special brain cells that make movement chemical dopamine die off, partly because brain immune cells (microglia) get angry and release toxins. Researchers tested VIP in mouse models of Parkinson's using a brain poison called LPS or MPTP. VIP saved a ton of those dopamine cells—up to 50-70% more survived. How? It turned off the bad microglia through its VPAC1 receiver, cutting poisons like iNOS, IL-1beta, and TNF-alpha (swelling signals). In one test, VIP-treated mice lost way fewer cells in the substantia nigra (the brain spot hit by Parkinson's). Another study confirmed it blocked brain cell death after toxin hits. This points to VIP as a brain protector, maybe slowing Parkinson's or other brain swelling diseases like Alzheimer's. It's exciting because current drugs don't fix the root immune problem well.

Study: Therapeutic Potential of Vasoactive Intestinal Peptide and its Receptors in Implant osseointegration
Benefits: Fights bone loss around dental or joint implants by calming immune overreactions that cause implants to fail. Improves bone healing and sticking.
Link: https://pmc.ncbi.nlm.nih.gov/articles/PMC8131842/
Summary: Implants like fake teeth or hip joints often fail because the body's defense system causes swelling and eats away bone nearby. This 2021 paper explores VIP's role. VIP chills out immune cells and boosts bone-building cells (osteoblasts) while taming bone-breaking ones (osteoclasts). In lab tests, VIP lowered swelling markers and helped cells around implants grow better. It binds to VPAC receptors on bone and immune cells, balancing the fight-or-heal response. Animal studies showed VIP-treated implants stuck to bone stronger with less swelling. For everyday people, this means fewer implant failures—super useful since millions get these each year. Early human clues suggest VIP sprays or coatings could make surgeries safer.

Study: Immunology of VIP: a review and therapeutical perspectives
Benefits: Balances the immune system, fights autoimmune diseases by shifting immune cells from attack mode to calm mode, helps allergies and gut swelling.
Link: https://pubmed.ncbi.nlm.nih.gov/11172702/
Summary: VIP is everywhere in the body, especially nerves and gut, acting like a peacekeeper for immunity. This 2001 review from PubMed explains how it stops overactive immune attacks in diseases like allergies, Crohn's, or rheumatoid arthritis. VIP switches "fighter" immune cells (Th1/Th17) to "helper" ones (Th2/Treg) that heal instead of harm. In tests, it cut swelling chemicals like TNF and boosted protectors like IL-10. Lab studies on immune cells showed VIP stopped them from going wild. For patients, this means potential relief from chronic swelling without steroids' bad side effects. It's being eyed for sprays or pills to treat asthma, IBD, or even COVID-like lung storms. Research shows promise in animal models of these diseases.

VIP – Research Links